SOURCES SOUGHT
A -- Receptor Profiling and Compound Library Screening
- Notice Date
- 10/17/2007
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6101 Executive Boulevard Room 260 - MSC 8402, Bethesda, MD, 20892, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- N01DA-8-8877
- Response Due
- 11/14/2007
- Archive Date
- 11/14/2007
- Point of Contact
- Diane Loeb, Contract Specialist, NIDA/NIH, Phone 301 443-6677, Fax 301 443-7595, - Craig Sager, Contracting Officer, NIDA/NIH, Phone (301) 443-6677, Fax (301) 443-7595
- E-Mail Address
-
dloeb@nida.nih.gov, cs591t@nih.gov
- Description
- This is a SOURCES SOUGHT NOTICE to determine the availability of small businesses (e.g., 8(a), veteran-owned small businesses, services-disabled veteran owned small businesses, HUB Zone small businesses, small disadvantaged businesses, and women-owned small businesses) having capability to perform receptor profiling and compound library screening. ***SUMMARY OF OBJECTIVES: One of the primary objectives of the NIDA's Division of Pharmacotherapies and Medical Consequences of Drug Abuse is to develop medications for the treatment of drug abuse and its consequences. When a compound appears to be a possible therapeutic candidate, there is a need for more extensive receptor profiling to insure that biological activity is specific to the systems of interest. Extensive profiling lessens the possibility of unexpected side effects in biological systems not specifically studied in the initial screens. This contract will provide a mechanism to profile selected compounds at a wide variety of receptor targets, ion channels and enzyme sites to assess the potential for side effects. The contract allows screening of a large number of substances from pharmaceutical or chemical compound libraries at selected receptors to discover novel compounds with specified biological activity. ***THE CONTRACTOR should be able to perform the following assays as a core battery, but also have the capacity to perform or develop other assays as needed by NIDA: NEUROTRANSMITTER related: Adenosine, non-selective; Adrenergic, alpha-1, non-selective;Adrenergic, alpha-2, non-selective; Adrenergic, beta-1;Cannabinoid, CB1; Cannabinoid, CB2;Dopamine, D4.2; GABA-A, agonist site; GABA-A, BDZ, alpha-1 site; GABA-B; Glutamate, AMPA site; Glutamate, Kainate site; Glutamate, NMDA agonist site; Glutamate, mGluR1 (metabotropic); Glutamate, mGluR5 (metabotropic); Glutamate, NMDA, Glycine (strychnine-insensitive site) (ionotropic); Glutamate, NMDA, PCP Site; Glycine, strychnine-sensitive; Histamine, H1; Histamine, H2; Histamine, H3; Muscarinic, M1; Muscarinic, M2;
- Record
- SN01435750-W 20071019/071017223347 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |